Navigation Links
Cancer Vaccines Poised to Reach $3 Billion in Sales by 2015
Date:4/19/2011

FALLS CHURCH, Va., April 19, 2011 /PRNewswire/ -- Technology Catalysts International (TCI), leading global consultants to the pharmaceutical industry, announced that research on cancer trends and development has identified cancer vaccines as a viable treatment option for a variety of cancers that currently have ineffective treatments.  The potential of the cancer vaccine market is forecast to approach $3 billion in 2015.

With the Medicare advisory committee's recent recommendation to support Dendreon's expensive prostate cancer vaccine, Provenge®, the field of cancer vaccines has received an unprecedented boost.  As a result, many companies are expected to enter this emerging and highly profitable field of preventing, treating, and potentially curing cancer. Prophylactic cancer vaccines, Gardasil® by Merck and Cervarix® by GSK, have already gained worldwide attention with their blockbuster status/potential.

Dr. Joseph Pantginis of Roth Capital Partners, a full service investment banking firm, recently evaluated the BiovaxID® technology from Biovest International and believes that this vaccine will be the next success, even though there are certain risks involved including the path to market for BiovaxID. However, in spite of the risks, Dr. Pantginis feels cancer immunology is coming of age and that BiovaxID can be successful even when two prior idiotype vaccines (developed by Genitope and Favrille) have failed.  According to Dr. Pantginis, there are two main reasons why BiovaxID is believed to have succeeded where the others have failed 1) critical data at the ASH 2010 conference were presented demonstrating that a vaccine against IgM and not igG is the reason for BiovaxID's success and 2) BiovaxID uses the entire idiotype from a patient to manufacture the vaccine whereas Genitope and Favrille used recombinant portions of the idiotype
'/>"/>

SOURCE Technology Catalysts International
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
2. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
3. Indevus Receives Approvable Letter From FDA for VALSTAR(R) for Bladder Cancer Therapy
4. EpiCept Reports Expansion of Clinical Development For Licensed Cancer Compound
5. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
6. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
7. Novel Technology Breaks Through Cancer Pain
8. CEL-SCI Secures Manufacturing Facility for Multikine Cancer Drug
9. Furamidine Found to Inhibit a Key Enzyme Involved in Cancer Cell DNA Repair Mechanisms
10. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
11. Peregrine Pharmaceuticals Doses First Patient in Cotara(R) Phase II Brain Cancer Trial In India
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/21/2014)... Aug. 21, 2014 Asterias Biotherapeutics, Inc. (OTCBB: ... of regenerative medicine, announced today the appointments of Andrew ... newly expanded Board of Directors. With these additions, the ... of whom are independent. Andy Arno ... emerging growth companies. He is currently Managing Director of ...
(Date:8/20/2014)... 20, 2014  The National Association of Drug ... achieved by the real-time, pseudoephedrine (PSE) blocking system ... Log Exchange (NPLEx), automatically blocks unlawful PSE sales ... offenders and make arrests. Data released by NPLEx ... blocked the sale of more than 32,105 ...
(Date:8/20/2014)... LUTHERVILLE, Md. , Aug. 20, 2014 /PRNewswire/ ... today lauded the latest results achieved by the ... known as the National Precursor Log Exchange (NPLEx), ... enforcement officials track down methamphetamine offenders and make ... in Missouri blocked the ...
Breaking Medicine Technology:Asterias Biotherapeutics Appoints Two Independent Directors and Announces Completion of Series A Common Stock Distribution 2Asterias Biotherapeutics Appoints Two Independent Directors and Announces Completion of Series A Common Stock Distribution 3Asterias Biotherapeutics Appoints Two Independent Directors and Announces Completion of Series A Common Stock Distribution 4Indiana's Stop-Sale System Achieves Significant Results In Battle Against Meth 2Missouri's Stop-Sale System Achieves Significant Results In Battle Against Meth 2
... is natural that all customers using the services of online ... for them and getting their order within the shortest possible ... and well-taken. This site assures new and regular clients with ... security. It uses the most updated methods to make every ...
... HeartWare International, Inc. (Nasdaq: HTWR ) (ASX: ... support technologies that are revolutionizing the treatment of advanced ... scheduled to make an investor presentation at the Canaccord ... 2010 at 9:00 a.m. Pacific Time (noon, Eastern Time). ...
Cached Medicine Technology:A New Online Pharmacy rxbuys.com by RX Corp Offers its Services to International Clients 2HeartWare to Present at the Canaccord Genuity Cardio/Diabetes & Obesity Conference 2
(Date:8/21/2014)... effective vaccination, polio is considered nearly eradicated. Each year ... scientists of the University of Bonn, together with colleagues ... that was able to resist the vaccine protection to ... outbreak in the Congo in 2010. The pathogen could ... results appear now in the magazine PNAS . ...
(Date:8/21/2014)... August 21, 2014 Glioblastoma Multiforme ... Therapeutic Approaches Target High Unmet Need in Newly ... of the Glioblastoma Multiforme (GBM) therapeutics market within ... and Japan. The report provides estimates of market ... 2020. It also covers disease epidemiology, treatment algorithms, ...
(Date:8/21/2014)... 2014 One of the emerging trends ... experience is an increasing adoption of non-invasive administration products. ... the patient through their convenient application, they find more ... a medical device used for the administration of drugs ... and paranasal sinus such as allergic and non-allergic rhinitis ...
(Date:8/21/2014)... Hospital officials, community leaders and elected officials ... new building at Mount Sinai Queens, marking the completion ... expansion and modernization project. During the event, hospital ... Kaufman, Chairman of the nearby Kaufman Astoria Studios, for ... will be named. The project, which began late ...
(Date:8/21/2014)... According to a new market research report "Near Field ... Auxiliary), Application (Payment, Transportation, Booking, Data Sharing, Service, Access ... - Global Forecasts to 2022", published by MarketsandMarkets, the ... by 2022 at an estimated CAGR of 8.83% from ... and 105 Figures spread through 298 Pages and in-depth ...
Breaking Medicine News(10 mins):Health News:Polio: Mutated virus breaches vaccine protection 2Health News:Asia-Pacific Glioblastoma Multiforme (GBM) Market Size Industry Analysis, Share, Growth, Trends and Forecast to 2020: MarketResearchReports.biz 2Health News:Asia-Pacific Glioblastoma Multiforme (GBM) Market Size Industry Analysis, Share, Growth, Trends and Forecast to 2020: MarketResearchReports.biz 3Health News:Asia-Pacific Glioblastoma Multiforme (GBM) Market Size Industry Analysis, Share, Growth, Trends and Forecast to 2020: MarketResearchReports.biz 4Health News:Asia-Pacific Glioblastoma Multiforme (GBM) Market Size Industry Analysis, Share, Growth, Trends and Forecast to 2020: MarketResearchReports.biz 5Health News:Asia-Pacific Glioblastoma Multiforme (GBM) Market Size Industry Analysis, Share, Growth, Trends and Forecast to 2020: MarketResearchReports.biz 6Health News:Asia-Pacific Glioblastoma Multiforme (GBM) Market Size Industry Analysis, Share, Growth, Trends and Forecast to 2020: MarketResearchReports.biz 7Health News:Intranasal Drug Delivery Market 2014 – 2018 Global Forecasts and Analysis in New Research Report at Sandlerresearch.org 2Health News:Intranasal Drug Delivery Market 2014 – 2018 Global Forecasts and Analysis in New Research Report at Sandlerresearch.org 3Health News:Intranasal Drug Delivery Market 2014 – 2018 Global Forecasts and Analysis in New Research Report at Sandlerresearch.org 4Health News:Intranasal Drug Delivery Market 2014 – 2018 Global Forecasts and Analysis in New Research Report at Sandlerresearch.org 5Health News:“Topping Off” Ceremony Marks Major Milestone in Mount Sinai Queens Construction Project 2Health News:“Topping Off” Ceremony Marks Major Milestone in Mount Sinai Queens Construction Project 3Health News:“Topping Off” Ceremony Marks Major Milestone in Mount Sinai Queens Construction Project 4Health News:Near Field Communication Market by Product (IC/Chips, Tags, Readers, and Auxiliary) Worth $16.25 Billion by 2022 – New Report by MarketsandMarkets 2Health News:Near Field Communication Market by Product (IC/Chips, Tags, Readers, and Auxiliary) Worth $16.25 Billion by 2022 – New Report by MarketsandMarkets 3Health News:Near Field Communication Market by Product (IC/Chips, Tags, Readers, and Auxiliary) Worth $16.25 Billion by 2022 – New Report by MarketsandMarkets 4
... , MONDAY, April 9 (HealthDay News) -- People ... problems, such as ulcers and bleeding, and also for ... The findings highlight the need to develop new ... arthritis patients, according to the Mayo Clinic researchers. ...
... than 60 percent of breast cancer survivors report at ... diagnosis, according to a new study led by a ... University of Pennsylvania. The findings are part of a ... late effects of breast cancer treatment and creating strategies ...
... , MONDAY, April 9 (HealthDay News) -- Hispanics and ... and Medicare and Medicaid patients are less likely to receive ... says. University of Michigan School of Public Health researchers ... were 1.5 times more likely to receive antidepressants than blacks ...
... , (WASHINGTON, April 9, 2012) A novel anti-leukemia compound with ... (T-ALL), suggesting its potential to become a new highly targeted ... according to results from a study published ... of the American Society of Hematology (ASH). ...
... 262 Pages | $29.95 | ISBN13: 9780199892594) "Roberta Ness teaches how ... as its subject, Dr. Ness shows how, with a little know-how and ... selves.", ... Medicine, National Academies of Science "Great science depends on innovative ...
... in-patient rehabilitation are more likely to land back in ... poorly, show signs of depression and lack social support ... Branch (UTMB) at Galveston. Hospital readmission for older adults ... billion annually. , Among the first of such ...
Cached Medicine News:Health News:Gastro Woes Often Strike Rheumatoid Arthritis Patients 2Health News:Breast cancer patients suffer treatment-related side effects long after completing care 2Health News:Breast cancer patients suffer treatment-related side effects long after completing care 3Health News:Minorities, Medicare Recipients Less Likely to Get Antidepressants 2Health News:Novel compound demonstrates anti-leukemic effect in zebrafish, shows promise for human treatment 2Health News:Novel compound demonstrates anti-leukemic effect in zebrafish, shows promise for human treatment 3Health News:Innovation Generation 2Health News:Innovation Generation 3Health News:Predictors identified for rehospitalization among post-acute stroke patients 2Health News:Predictors identified for rehospitalization among post-acute stroke patients 3
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
Medicine Products: